Pegacaristim

Drug Profile

Pegacaristim

Alternative Names: KRN 9000; Megakaryocyte growth and development factor; MGDF; PEG thrombopoietin - Kirin-Amgen; PEG-MGDF; PEG-rHuMGDF; PEG-rMGDF; Pegylated megakaryocyte growth and development factor; Pegylated recombinant megakaryocyte growth and development factor; Polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor; Thrombopoietin - Kirin-Amgen

Latest Information Update: 29 Feb 2008

Price : $50

At a glance

  • Originator Amgen; Kirin Brewery; ZymoGenetics
  • Developer Amgen; Kirin Holdings Company; ZymoGenetics
  • Class Antineoplastics; Growth factors
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemoprotection; Thrombocytopenia

Most Recent Events

  • 29 Feb 2008 Discontinued - Phase-II for Thrombocytopenia (Chemotherapy-induced) in Japan (unspecified route)
  • 13 Jan 2005 No development reported - Phase-II for Thrombocytopenia (Chemotherapy-induced) in Japan (unspecified route)
  • 13 Jan 2005 Discontinued - Clinical-Phase-Unknown for Thrombocytopenia (Chemotherapy-induced) in Europe (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top